SUBSCRIBE: RSS Feed for Spinal Cord Injury Zone Email Updates Follow Spinal Cord Injury Zone on Twitter Spinal Cord Injury Zone on Facebook

Browsing Articles by Date

Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study

Published: July 10, 2017 | Category: News | Spinal Cord Injury:

Ability to enroll patients with second most common cervical spinal cord injury broadens eligible population for SCiStar study and future trials

FREMONT, Calif., July 10, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s amendment to the clinical research protocol for its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in motor complete cervical spinal cord injury (SCI). The amendment expands the eligibility criteria to include patients with a C-4 spinal cord injury and extends the dosing window from 14 to 30 days to 21 to 42 days post-injury. Continue Reading »